Wikipedia -WSS

Wikipedia

author：focus 2025-10-01 21:40:49 - browse：37524

Adam's take main illustration — Molly Ferguson/STAT

Novartis said Monday that it intends to buy MorphoSys for just under $3 billion. The deal will not close. Six months from now, or sooner, Novartis will walk away — slightly embarrassed but otherwise unscathed — happy to pay a small breakup fee to MorphoSys to avoid owning a drug for myelofibrosis that regulators turned away.

MorphoSys will not fare as well from the breakup. Its future, and that of the drug called pelabresib at the center of the deal, will be thrown into limbo.

This is all speculation on my part, but it’s supported by separate conversations with two people familiar with pelabresib and the debate inside Novartis over the MorphoSys acquisition. They requested anonymity to discuss confidential matters.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： The battle over 'scope creep' and who gets to be called 'doctor'

Wikipedia

WSS

Philips to halt sales of sleep apnea machines in U.S.

Readout Newsletter: CG Oncology IPO, Eli Lilly, Tesla, Merck

Will the FTC rein in IQVIA's health data empire?

Vertex non

Zyn nicotine pouches become unlikely player in latest culture war

New Alzheimer's drugs heat up race for early detection blood tests

knowledge

Wikipedia

entertainment

At least 13 dead in Texas as scorching temps continue

Rise in cancer among younger people worries and puzzles doctors

Medicare proposal to cover medical devices draws a mixed reaction

Reconstructing family trees of blood cells may help predict disease

How one medical school became remarkably diverse

Search called off for baby washed away in Pennsylvania flash flood

State Dept. review finds Biden bears some blame for Afghanistan failures

New lawsuit accuses health insurer Cigna of denying claims in bulk

Wildfire smoke exposes gaps in outdoor worker protections

Democrats decry new health bill for going easy on private equity

explore

The haunting brain science of long Covid

New Alzheimer's drugs heat up race for early detection blood tests

Roche’s Alnylam deal shows drug firms interested in heart drugs

The battle over 'scope creep' and who gets to be called 'doctor'

Boston competes with Raleigh

UHS says company favors patients whose insurance pays more

Wikipedia

knowledge

leisure time

focus